Fapon Biopharma
- | Biotech or pharma, therapeutic R&D
Fapon Biopharma has developed innovative technology platforms, including:
- Antibody-cytokine fusion
- T-cell engagers
- Multispecific antibodies
- Intracellular biologics degrader
From these platforms, we offer several programs available for licensing or co-development, including:
- FP-008: PD1-IL10M for oncology, planned IND submission in Q1 2025
- Other IL10M fusions with tumor antigens such as EGFR and VEGFR2 (IND-enabling stage)
- IL10 immune suppressive construct antibody-fusion for autoimmune indications
- Trispecific TIGIT/PVRIG/PDL1 (IND-enabling stage)
- Novel T-cell engagers at discovery stages for cancer and autoimmune indications
- PROTiNb targeting intracellular molecules .
Address
DongguanChina
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}